Core Viewpoint - Dyne Therapeutics has received Breakthrough Therapy Designation from the FDA for DYNE-101, aimed at treating myotonic dystrophy type 1 (DM1), and has outlined a revised plan for U.S. Accelerated Approval based on new long-term functional data [1][2][10]. Group 1: FDA Designations and Approvals - The FDA granted Breakthrough Therapy Designation to DYNE-101 for DM1, which expedites development and review for drugs showing substantial improvement over existing therapies [10]. - Dyne is pursuing U.S. Accelerated Approval for DYNE-101, with a revised protocol submitted to the FDA following a Type C meeting [6][5]. Group 2: Clinical Trial Updates - The ongoing Registrational Expansion Cohort of the ACHIEVE trial will enroll 60 participants, with video hand opening time (vHOT) as the primary endpoint for potential Accelerated Approval [6][5]. - New long-term data from the ACHIEVE trial indicate that DYNE-101 led to a 3.3 seconds improvement in vHOT at 6 months compared to placebo, with sustained improvements observed at 12 months [12]. - The trial's secondary endpoints include various measures of muscle strength and performance, with a reported 20% improvement in strength at 12 months relative to baseline [12]. Group 3: Financial Guidance - As of March 31, 2025, Dyne reported cash, cash equivalents, and marketable securities totaling $677.5 million, expected to fund operations into Q4 2026 [7]. Group 4: Future Plans - Dyne plans to complete enrollment in the Registrational Expansion Cohort by Q4 2025, with data expected in mid-2026 to support a potential U.S. Accelerated Approval submission in late 2026 [6]. - A confirmatory Phase 3 clinical trial is anticipated to begin in Q1 2026 [6].

Core Insights - Dyne Therapeutics plans to provide an update on DYNE-101 for myotonic dystrophy type 1 (DM1) on June 17, 2025, with a webcast scheduled for 8:00 a.m. ET [1] - The company is focused on developing innovative therapeutics for genetically driven neuromuscular diseases, utilizing its FORCE™ platform to enhance delivery to muscle tissue and the central nervous system [3] Company Overview - Dyne Therapeutics is dedicated to discovering and advancing life-transforming therapeutics for individuals with genetically driven neuromuscular diseases [3] - The company has a diverse pipeline that includes clinical programs for DM1 and Duchenne muscular dystrophy (DMD), as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD) [3] Investor Engagement - A live webcast of the update will be available on Dyne's website, with a replay accessible for 90 days post-presentation [2] - An accompanying slide presentation will also be provided during the webcast [2]

Core Insights - Dyne Therapeutics announced new preclinical data for DYNE-302, showing potential functional improvement in facioscapulohumeral muscular dystrophy (FSHD) [1][2] - The data will be presented at the 32nd Annual FSHD Society's International Research Congress in Amsterdam on June 12-13, 2025 [1][4] Company Overview - Dyne Therapeutics is focused on developing therapeutics for genetically driven neuromuscular diseases, leveraging its FORCE™ platform [6] - The company has a broad pipeline that includes clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as preclinical programs for FSHD and Pompe disease [6] Disease Background - FSHD is a rare, progressive genetic disease caused by a mutation in the DUX4 gene, leading to muscle loss and weakness [5] - An estimated 16,000 to 38,000 individuals in the U.S. and approximately 35,000 in Europe are affected by FSHD, with no approved therapies currently available [5] Research Findings - In a mouse model of severe FSHD, a single intravenous dose of DYNE-302 restored the ability to run on a treadmill, indicating potential reversal of muscle damage and inflammation [2][3] - DYNE-302 targets DUX4 mRNA to suppress its expression, aiming to address the underlying cause of muscle damage in FSHD [3] Presentation Details - The oral presentation on DYNE-302's effects will take place on June 13, 2025, at 12:00 p.m. CEST [4] - The presentation will be available on Dyne's website following the session [4]

"Our two lead programs continue to demonstrate compelling and favorable data, including evidence of functional improvement across multiple measures in DM1 and DMD. We are urgently advancing both programs toward potential U.S. Accelerated Approval submissions in 2026 and possible commercial launches in 2027," said John Cox, president and chief executive officer of Dyne. "I am also thrilled to welcome Erick, Vik and Ron to the Dyne leadership team, which now includes a new role for Oxana as chief innovation o ...

Core Insights - Dyne Therapeutics is advancing its lead programs DYNE-101 and DYNE-251 towards potential U.S. Accelerated Approval submissions in 2026, with possible commercial launches in 2027 [2][5] Regulatory Developments - A Type C meeting with the FDA's CDER was held in May 2025 to discuss the regulatory path for DYNE-101 in DM1, with plans for a regulatory update following the receipt of meeting minutes [1][5] - The Registrational Expansion Cohort of the ACHIEVE Trial for DYNE-101 has been initiated, aiming for full enrollment by mid-2025 and data reporting in H1 2026 to support a potential BLA submission [1][5] - The Registrational Expansion Cohort of the DELIVER Trial for DYNE-251 has been fully enrolled, with data expected in late 2025 and a potential BLA submission anticipated in early 2026 [1][5] Financial Performance - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $677.5 million, sufficient to fund operations into the second half of 2026 [7] - Research and development expenses for Q1 2025 were $106.4 million, a significant increase from $44.5 million in Q1 2024 [7][8] - General and administrative expenses decreased to $15.9 million in Q1 2025 from $24.6 million in Q1 2024 [8] - The net loss for Q1 2025 was $115.4 million, or $1.05 per share, compared to a net loss of $65.6 million, or $0.81 per share, in Q1 2024 [8][14] Leadership Changes - Dyne has strengthened its leadership team with new appointments, including Erick Lucera as CFO, Vikram Ranade as CBO, and Ranjan Batra as CSO, to support the company's late-stage clinical and commercialization plans [2][5][11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39509 Dyne Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 3 ...

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that the European Commission (EC) has granted orph ...